News & Videos - ORAMED PHARMACEUTICALS INC.

Oramed Letter to Shareholders PR Newswire NEW YORK, Feb. 20, 2024 Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing NEW YORK , Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to...

Thinking about buying stock in MicroAlgo, Oramed Pharmaceuticals, Limbach Holdings, Niu Technologies, or Applied Molecular Transport? PR Newswire NEW YORK, Sept. 22, 2023 NEW YORK , Sept. 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MLGO, ORMP, LMB, NIU, and AMTI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. MLGO:...

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company PR Newswire NEW YORK, Sept. 21, 2023 18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase Agreement and DIP Term Loan with Sorrento Therapeutics NEW YORK , Sept. 21, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:...

Oramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology Globally PR Newswire NEW YORK, Aug. 2, 2023 JV will have global marketing rights to oral drug delivery technology HTIT to invest $60 million , Oramed to invest $10 million into JV HTIT to provide a supply agreement for oral insulin capsule JV to advance registration of oral insulin in the United States and other countries NEW YORK , Aug. 2, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc....

Oramed to Present at the 83rd American Diabetes Association Conference PR Newswire NEW YORK, June 20, 2023 NEW YORK , June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association's 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California . The presentation will include an overview of data from Oramed's...

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit PR Newswire NEW YORK, May 18, 2023 NEW YORK , May 18, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA , on May 31, 2023 . The presentation will include an overview of Oramed's oral delivery technology...

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China PR Newswire NEW YORK, May 15, 2023 Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups NEW YORK , May 15, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ) announced today that Hefei...

Thinking about buying stock in Zillow, Li Auto, Endeavour Silver, Protalix Biotherapeutics, or Oramed Pharmaceuticals? PR Newswire NEW YORK, May 4, 2023 NEW YORK , May 4, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for Z, LI, EXK, PLX, and ORMP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. Z:...

Oramed Appoints Ben Shapiro to its Board of Directors PR Newswire NEW YORK, May 1, 2023 NEW YORK , May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") ( www.oramed.com ) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023 . The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market. Ben Shapiro is a successful entrepreneur...

Oramed Pharmaceuticals Issues Shareholder Update PR Newswire NEW YORK, Feb. 9, 2023 NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials. In addition, management and the Board of Directors are examining the Company's existing pipeline and conducting a comprehensive review of strategic alternatives...

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes PR Newswire NEW YORK, Jan. 11, 2023 NEW YORK , Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of...

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK , Jan. 4, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating...

Oramed Letter to Shareholders PR Newswire NEW YORK, Dec. 21, 2022 Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023 Phase 2 NASH Trial Achieved Primary and Secondary Endpoints Definitive Deal Signed to Commercialize Oral Insulin in South Korea $160 Million in Cash and Investments (as of September 30, 2022 ) NEW YORK , Dec. 21, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the...

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism PR Newswire NEW YORK, Nov. 29, 2022 NEW YORK , Nov. 29, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled: " Oral Insulin (ORMD-0801) in Type 2...

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH PR Newswire NEW YORK, Nov. 17, 2022 Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH. Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids. Key opinion leaders' discussion highlights new data and is available on demand. NEW YORK , Nov. 17, 2022...

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea PR Newswire NEW YORK, Nov. 14, 2022 Medicox to Distribute Oramed's Oral Insulin in South Korea , if approved Oramed to Receive Up to $18 Million in Developmental Milestones Oramed to Receive up to 15% Royalties on Gross Sales Large Market Potential: 1 in 7 Koreans Over Age 30 Has Diabetes NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ( www.oramed.com ), a...

Oramed Reports Third Quarter 2022 Financial Results PR Newswire NEW YORK, Nov. 10, 2022 NEW YORK , Nov. 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its financial results for the quarter ended September 30, 2022 . "We are pleased to share our quarterly report for the third quarter of 2022. We had a...

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH PR Newswire NEW YORK, Nov. 9, 2022 Webinar scheduled for Thursday, November 17, 2022 , at 11:00 a.m. EST Featuring key opinion leader discussion on current treatment landscape NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral...

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine PR Newswire NEW YORK, Oct. 7, 2022 Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept for oral delivery of vaccines using Oravax technology NEW YORK , Oct. 7, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com...

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate PR Newswire NEW YORK, Sept. 13, 2022 Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatment of NASH using Oramed's oral insulin NEW YORK , Sept. 13, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ),...